190 related articles for article (PubMed ID: 9044313)
21. Administration of AGEs in vivo induces extracellular matrix gene expression.
Striker LJ; Striker GE
Nephrol Dial Transplant; 1996; 11 Suppl 5():62-5. PubMed ID: 9044310
[TBL] [Abstract][Full Text] [Related]
22. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice.
Schwedler SB; Verbeke P; Bakala H; Weiss MF; Vilar J; Depreux P; Fourmaintraux E; Striker LJ; Striker GE
Diabetes Obes Metab; 2001 Aug; 3(4):230-9. PubMed ID: 11520302
[TBL] [Abstract][Full Text] [Related]
23. Advanced glycosylation end products in diabetic renal and vascular disease.
Bucala R; Vlassara H
Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of Nsigma-(carboxy-methyl)lysine and changes in glomerular extracellular matrix components in Otsuka Long-Evans Tokushima fatty rat: a model of spontaneous NIDDM.
Kushiro M; Shikata K; Sugimoto H; Ikeda K; Horiuchi S; Makino H
Nephron; 1998 Aug; 79(4):458-68. PubMed ID: 9689163
[TBL] [Abstract][Full Text] [Related]
25. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy.
Cohen MP; Ziyadeh FN
J Am Soc Nephrol; 1996 Feb; 7(2):183-90. PubMed ID: 8785386
[TBL] [Abstract][Full Text] [Related]
26. Localization of advanced glycation endproducts in the kidney of experimental diabetic rats.
Shikata K; Makino H; Sugimoto H; Kushiro M; Ota K; Akiyama K; Araki N; Horiuchi S; Ota Z
J Diabetes Complications; 1995; 9(4):269-71. PubMed ID: 8573744
[TBL] [Abstract][Full Text] [Related]
27. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy.
Nishino T; Horii Y; Shiiki H; Yamamoto H; Makita Z; Bucala R; Dohi K
Hum Pathol; 1995 Mar; 26(3):308-13. PubMed ID: 7890283
[TBL] [Abstract][Full Text] [Related]
29. [Molecular bases of diabetic nephropathy].
Lagranha CJ; Fiorino P; Casarini DE; Schaan BD; Irigoyen MC
Arq Bras Endocrinol Metabol; 2007 Aug; 51(6):901-12. PubMed ID: 17934656
[TBL] [Abstract][Full Text] [Related]
30. Diffuse glomerular nodular lesions in diabetic pigs carrying a dominant-negative mutant hepatocyte nuclear factor 1-alpha, an inheritant diabetic gene in humans.
Hara S; Umeyama K; Yokoo T; Nagashima H; Nagata M
PLoS One; 2014; 9(3):e92219. PubMed ID: 24647409
[TBL] [Abstract][Full Text] [Related]
31. Three-dimensional architecture of glomerular extracellular matrices in diabetic glomerulosclerosis.
Makino H; Nishimura S; Haramoto T; Yamasaki Y; Ikeda S; Ota Z
J Diabet Complications; 1991; 5(2-3):124-5. PubMed ID: 1770017
[TBL] [Abstract][Full Text] [Related]
32. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
Boor P; Celec P; Behuliak M; Grancic P; Kebis A; Kukan M; Pronayová N; Liptaj T; Ostendorf T; Sebeková K
Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
[TBL] [Abstract][Full Text] [Related]
33. Mitofusin 2 attenuates the histone acetylation at collagen IV promoter in diabetic nephropathy.
Mi X; Tang W; Chen X; Liu F; Tang X
J Mol Endocrinol; 2016 Nov; 57(4):233-249. PubMed ID: 27997345
[TBL] [Abstract][Full Text] [Related]
34. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
McLennan SV; Kelly DJ; Schache M; Waltham M; Dy V; Langham RG; Yue DK; Gilbert RE
Kidney Int; 2007 Aug; 72(4):481-8. PubMed ID: 17554258
[TBL] [Abstract][Full Text] [Related]
35. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
Zhuang A; Forbes JM
Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.
Niwa T; Katsuzaki T; Miyazaki S; Miyazaki T; Ishizaki Y; Hayase F; Tatemichi N; Takei Y
J Clin Invest; 1997 Mar; 99(6):1272-80. PubMed ID: 9077536
[TBL] [Abstract][Full Text] [Related]
37. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
Yuan Y; Sun H; Sun Z
Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
[TBL] [Abstract][Full Text] [Related]
38. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
[TBL] [Abstract][Full Text] [Related]
39. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation.
Abe H; Matsubara T; Iehara N; Nagai K; Takahashi T; Arai H; Kita T; Doi T
J Biol Chem; 2004 Apr; 279(14):14201-6. PubMed ID: 14732718
[TBL] [Abstract][Full Text] [Related]
40. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products.
Beisswenger PJ; Howell SK; Russell GB; Miller ME; Rich SS; Mauer M
Diabetes Care; 2013 Oct; 36(10):3234-9. PubMed ID: 23780945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
